Clinical Data

Summit’s PD-1/VEGF to take center stage at ASCO, with wide impact for peers

BioSpace

As Summit Therapeutics' Chinese partner prepares to reveal data for a key trial at ASCO, analysts consider the impact on rivals Merck, Bristol Myers Squibb and BioNTech.

Oncology

Read full story

pharminent May 29, 2026 (Last updated: May 29, 2026)

BioSpace

As Summit Therapeutics’ Chinese partner prepares to reveal data for a key trial at ASCO, analysts consider the impact on rivals Merck, Bristol Myers Squibb and BioNTech.

Oncology

Read full story

Related Stories

ASCO: BMS hails “compelling” phase 3 celmod readout

GSK, Ionis unveil data for hepatitis B drug touted as ‘functional cure’

GSK hails ‘unprecedented’ cure rates with hep B drug

You May Have Missed

ASCO: BMS hails “compelling” phase 3 celmod readout

Summit’s PD-1/VEGF to take center stage at ASCO, with wide impact for peers

Pfizer bets up to $10.5B in 12-candidate cancer collab with China’s Innovent

Ahead of ASCO data drop, AZ gets key Imfinzi approval